Safety & Performance Study of Lumen Biomedical's FiberNet Distal Protection System for the Treatment of Renal Artery Stenosis (FORTRESS)

VIVA Physicians

Status: Unknown

Conditions: Renal Stenting in the Treatment of Pts w/a High Grade Ostial Atherosclerotic Renal Lesion(s).

Treatments: Device: Lumen Biomedical FiberNet Embolic Protection System

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00674505

G070189/S002

Details and patient eligibility

About

To evaluate the procedural safety and filter efficiency of the FiberNet® Embolic Protection System when used in conjunction with the Boston Scientific Express SD Stent System for primary stenting of ostial atherosclerotic renal lesions in patients with atherosclerotic renal artery stenosis.

Enrollment: 20 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥ 18 and ≤ 85 years.

2. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed an IRB approved consent form.

3. Subject understands the duration of the study and it's follow up visit requirements.

4. Unilateral or bilateral atherosclerotic de novo renal artery stenosis (RAS) associated with any or all of the following:

   1. SBP >140 despite ≥3 anti-hypertensive medications
   2. Estimated Glomerular Filtration Rate (eGFR) ≥30-≤70 cc/min calculated using the Modified Diet in Renal Disease (MDRD) formula
   3. Recurrent episodes of decompensated heart failure
   4. Recurrent episodes of "flash" pulmonary edema

Angiographic Inclusion Criteria

1. ≥70% <100% renal artery stenosis (by visual estimate) involving unilateral, bilateral renal arteries or solitary renal artery.
2. Renal pole-to-pole length >7cm.
3. Lesion ≤15 mm from the aorto-ostial junction.
4. Renal artery reference lumen diameter ≥3.5 - ≤7 mm for FiberNet placement.

Exclusion criteria

Clinical Exclusion Criteria

1. Estimated life expectancy <12 months.
2. Estimated Glomerular Filtration Rate (eGFR) <30 cc/min.
3. Renal pole-to-pole length <7cm on side of diseased kidney.
4. No history of transplanted kidneys or polycystic kidney disease.
5. Uncontrolled hypercoagulability.
6. Known allergies or sensitivities to heparin, aspirin, other anti-coagulant/antiplatelet therapies, nitinol and stainless steel.
7. Known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure.
8. Patient refuses possible temporary or permanent hemodialysis.
9. Refuses possible surgery for repair of access site or renal artery.
10. Known severe coronary or carotid disease likely to require surgical treatment after enrollment or during follow-up period.
11. Uncompensated congestive heart failure.
12. Current enrollment in any investigational study wherein patient participation has not been completed.
13. Cardiovascular surgical or cardiovascular interventional procedures (including, but not limited to, aortic, renal, cardiac, carotid, femoro-popliteal, and below the knee) within 30 days prior to enrollment in this study.
14. Planned or predicted cardiovascular surgical or interventional procedures outside of the affected renal artery (including, but not limited to, aortic, renal, cardiac, carotid, contralateral femoro-popliteal, and contralateral below the knee) within 30 days after entry into this study and prior to completion of the 30 day follow-up.
15. Pregnancy, breast-feeding or plans to become pregnant in female of child bearing potential.
16. Any patient who in the opinion of the investigator would not be a good candidate for enrollment.

Angiographic Exclusion Criteria

1. Early bifurcation of the main renal artery preventing complete embolic protection of the kidney with the FiberNet.
2. Fibromuscular Dysplasia.
3. Presence of thrombus at the lesion site.
4. Non-ostial atherosclerosis (lesion >15mm from the renal ostium).
5. Subintimal guidewire placement resulting in dissection of the renal artery or aorta, or perforation of the renal artery or aorta prior to deployment of the device.
6. Severe calcification likely to prevent the passage of the device. -

Trial design

20 participants in 1 patient group

Treatment, Open label, Single Group Assignment

Other group

Treatment:

Device: Lumen Biomedical FiberNet Embolic Protection System